Treatment methods using anti-CD22 antibodies
OwnerJoseph Tuscano, Thomas F. Tedderinventors
Life of this patent
Estimating the term…
Abstract
The invention concerns treatment methods using anti-CD22 monoclonal antibodies with unique physiologic properties. In particular, the invention concerns methods for the treatment of B-cell malignancies by administering an effective amount of a blocking anti-CD22 monoclonal antibody specifically binding to the first two Ig-like domains, or to an epitope within the first two Ig-like domains of native human CD22 (hCD22).
Claims38
A method for treating a human patient diagnosed with a B-cell malignancy, comprising (1) administering to said human patient an effective amount of a blocking anti-CD22 monoclonal antibody binding to the first two Ig-like domains, or to an epitope within the first two Ig-like domains of native human CD22 (hCD22) of SEQ ID NO:
- 1, and (2) monitoring the response of said malignancy to said treatment.
Dependencies are inferred from the claim text.